StockData
Obsidian Therapeutics, Inc. logo

Obsidian Therapeutics, Inc. (OBX) stock

OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)

Close on Nov 20, 2026Market cap $741.28MP/E –Yield –

Obsidian Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$50.66M–
Q2 FY2026Jun 30, 2026-$25.86M–
Q1 FY2026Apr 10, 2026-$19.63M–
Q3 FY2025Sep 30, 2025-$28.47M–
Q2 FY2025Jun 30, 2025-$26.90M–
Q1 FY2025Mar 31, 2025-$24.99M–

More Obsidian Therapeutics figures

See a number that looks wrong?